Wagenlehner FME, et al. - In this investigation, researchers assessed the noninferiority of plazomicinan (an aminoglycoside with bactericidal activity against multidrug-resistant resistant Enterobacteriaceae) to meropenem for treating complicated urinary tract infections (UTIs), including acute pyelonephritis, with a noninferiority margin of 15 percentage points.

For this analysis, 609 patients with complicated UTIs, including acute pyelonephritis, were randomly assigned in a 1:1 ratio to intravenous plazomicin (15 mg per kilogram of body weight once daily) or meropenem (1 g every 8 hours), with optional oral step-down therapy after at least 4 days of intravenous therapy, for a total of 7 to 10 days of therapy.

For the treatment of complicated UTIs and acute pyelonephritis caused by Enterobacteriaceae, including multidrug-resistant strains, plazomicin once daily was not inferior to meropenem.